Traws Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Traws PharmaDer Gewinn des Unternehmens wird voraussichtlich um 20.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 11.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-20.1%

Wachstumsrate der Gewinne

-4.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	11.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Mar 09

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Apr 22

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

Jul 27

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

Mar 21

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

Dec 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:TRAW - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	0	-33	N/A	N/A	1
12/31/2025	0	-28	N/A	N/A	1
12/31/2024	0	-23	N/A	N/A	2
3/31/2024	0	-18	-18	-18	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-20	-17	-17	N/A
6/30/2023	0	-21	-17	-17	N/A
3/31/2023	0	-21	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-17	-17	-17	N/A
6/30/2022	0	-15	-17	-17	N/A
3/31/2022	0	-16	-17	-17	N/A
12/31/2021	0	-16	-19	-19	N/A
9/30/2021	0	-19	-21	-21	N/A
6/30/2021	0	-22	-22	-22	N/A
3/31/2021	0	-25	-23	-23	N/A
12/31/2020	0	-25	-23	-23	N/A
9/30/2020	0	-24	-23	-23	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	2	-19	-21	-21	N/A
12/31/2019	2	-22	-21	-21	N/A
9/30/2019	2	-21	-21	-21	N/A
6/30/2019	2	-22	-24	-24	N/A
3/31/2019	1	-23	-24	-24	N/A
12/31/2018	1	-21	-23	-23	N/A
9/30/2018	1	-21	-22	-22	N/A
6/30/2018	1	-23	-22	-22	N/A
3/31/2018	1	-21	-23	-23	N/A
12/31/2017	1	-24	N/A	-24	N/A
9/30/2017	1	-23	N/A	-24	N/A
6/30/2017	2	-18	N/A	-19	N/A
3/31/2017	4	-21	N/A	-17	N/A
12/31/2016	6	-20	N/A	-16	N/A
9/30/2016	15	-11	N/A	-16	N/A
6/30/2016	15	-15	N/A	-22	N/A
3/31/2016	13	-19	N/A	-26	N/A
12/31/2015	11	-24	N/A	-31	N/A
9/30/2015	2	-41	N/A	-40	N/A
6/30/2015	0	-50	N/A	-46	N/A
3/31/2015	0	-57	N/A	-51	N/A
12/31/2014	1	-64	N/A	-58	N/A
9/30/2014	3	-65	N/A	-61	N/A
6/30/2014	4	-71	N/A	-62	N/A
3/31/2014	4	-68	N/A	-64	N/A
12/31/2013	5	-65	N/A	-61	N/A
9/30/2013	6	-62	N/A	-72	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRAW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRAW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRAW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRAWDie Einnahmen des Unternehmens (11.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: TRAWDie Einnahmen des Unternehmens (11.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRAW in 3 Jahren voraussichtlich hoch sein wird

Traws Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus EPS estimates upgraded to US$0.97 loss

Consensus revenue estimates fall by 13%

Consensus forecasts updated

Price target decreased to US$8.67

Price target decreased to US$10.00

Recent updates

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Onconova Therapeutics, Inc. Announces Board Appointments

Consensus forecasts updated

Price target decreased to US$8.67

Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022

Onconova Therapeutics, Inc. Announces Executive Changes

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.00

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

Price target decreased to US$11.50

Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer

Onconova Therapeutics names Mark Gelder as chief medical officer

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer

Onconova Therapeutics announces $8.7M registered direct offering

Onconova cleared to start Phase 1 trial for cancer therapy

Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Manoj Maniar, Ph.D., Senior Vice President, Product Development departs from Onconova Therapeutics, Inc

Onconova Therapeutics Files Investigational New Drug Application for Multi-Kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics EPS in-line, misses on revenue

Onconova Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Onconova Therapeutics, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie